A Phase 2 interventional study of Seladelpar and Placebos in NASH - Nonalcoholic Steatohepatitis, sponsored by Gilead Sciences. Terminated at 14 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-09-15.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Gilead Sciences.
Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, this one is the 8th largest by enrollment, is one of 2 that started in 2018, is one of 11 in phase 2, and was the 14th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →None of the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 181 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 161 across the 16 interventional studies. Of the 16 that completed or were terminated, 15 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Phase 2, Double-Blind (DB), Randomized, Placebo-Controlled Study Followed by an Open-Label Extension Period to Evaluate the Activity of Seladelpar in Subjects with Nonalcoholic Steatohepatitis (NASH)
OLE phase was not analyzed due to the early termination of the study
Primary Objectives
Secondary Objectives
DB Inclusion Criteria:
DB Exclusion Criteria:
Hepatic decompensation defined as the presence of any of the following:
Other chronic liver diseases
History of diagnosed or treated within 2 years
Patients unable to undergo MRI-PDFF due to:
OLE Phase Enrollment Criteria
Subjects must fulfill the following before allowing to start OLE dosing:
Meet the above DB phase Inclusion and Exclusion Criteria before Day 1 of the OLE phase, with the exception of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
Drug: Seladelpar
Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
Drug: Seladelpar
Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
Drug: Seladelpar
Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
Drug: Placebos
10 mg, 20 mg, or 50 mg
Also known as: MBX-8025
Matching placebo Capsule
Percentage Change From Baseline in Magnetic Resonance Imaging-proton Density Fat Fraction (MRI-PDFF)
Evaluate the effect of seladelpar on hepatic fat fraction, as assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at Week 12 in the double-blind (DB) phase. MRI-PDFF Relative (Percent) Change From Baseline to Week 12 - ANCOVA - mITT Population MRI-PDFF exam was used to quantify the hepatic proton density fat fraction noninvasively. The fat fraction is the proportion of mobile protons in liver tissue attributable to fat and thus, is a noninvasive magnetic resonance-based biomarker of liver triglyceride concentration.
Time frame: Week 12
Percentage of Participants With Improvement of 2 Points or More in the Nonalcoholic Fatty Liver Disease Activity Score (NAS)
Histopathology nonalcoholic fatty liver disease activity score (NAS) change from baseline ≤-2 (Improvements of 2 points or more in NAS) - mITT Population Total NAS score represents the sum of scores for steatosis, lobular inflammation, and ballooning, and ranges from 0-8. Diagnosis of NASH (or, alternatively, fatty liver not diagnostic of NASH) should be made first, then NAS is used to grade activity. NAS scores of 0-2 occurred in cases largely considered not diagnostic of NASH, scores of 3-4 were evenly divided among those considered not diagnostic, borderline, or positive for NASH. Scores of 5-8 occurred in cases that were largely considered diagnostic of NASH
Time frame: Week 52
Percent Change From Baseline in Alanine Aminotransferase (ALT) at Week 12 and Week 52
Alanine Aminotransferase (ALT) Relative (percent) change of from Baseline to Weeks 12 and Week 52 - mITT Population A decreased serum levels of alanine aminotransferase (ALT) is a marker of liver function improvement.
Time frame: Week 12, Week 52
Percent Change From Baseline in Aspartate Aminotransferase (AST) at Week 12 and Week 52
Relative (Percent) Change of Aspartate Aminotransferase (AST) From Baseline to Weeks 12 and Week 52 - mITT Population A decreased serum levels of Aspartate Aminotransferase (AST) is a marker of liver function improvement.
Time frame: Weeks 12, Week 52
Percent Change From Baseline in Gamma Glutamyl Transferase (GGT) at Week 12 and Week 52
Relative (Percent) Change of Gamma Glutamyl Transferase (GGT) From Baseline to Weeks 12 and Week 52 - mITT Population A decreased serum levels of Gamma Glutamyl Transferase (GGT) is a marker of liver function improvement.
Time frame: Weeks 12, Week 52
Number of Participants With Decrease in MRI-PDFF ≥ 30% From Baseline at Week 12 and Week 52
Number of Participants with a relative decrease in MRI-PDFF ≥30% (ie, percent change ≥ 30%) at Weeks 12, and 52/ET (Early Termination) in the DB phase - mITT Population. MRI-PDFF exam was used to quantify the hepatic proton density fat fraction noninvasively. The fat fraction is the proportion of mobile protons in liver tissue attributable to fat and thus, is a noninvasive magnetic resonance-based biomarker of liver triglyceride concentration. MRI-PDFF response defined as ≥30% relative decline in MRI-PDFF is associated with ≥1 stage improvement in fibrosis and may be used as a surrogate marker of fibrosis regression in early phase clinical trials for NASH
Time frame: Week 12, Week 52
Percentage Change From Baseline in Magnetic Resonance Imaging-proton Density Fat Fraction (MRI-PDFF) at Week 52
Percentage Change from Baseline in MRI-PDFF to Weeks 52//ET - mITT Population MRI-PDFF exam was used to quantify the hepatic proton density fat fraction noninvasively. The fat fraction is the proportion of mobile protons in liver tissue attributable to fat and thus, is a noninvasive magnetic resonance-based biomarker of liver triglyceride concentration.
Time frame: Week 52
Number of Liver Biopsy Responders With Reversal of NASH Reversal of NASH (Ballooning Score of 0 and Lobular Inflammation Score of 0 or 1) and no Worsening of Hepatic Fibrosis at Week 52
Liver Biopsy Responders with reversal of NASH (ballooning score of 0 and lobular inflammation score of 0 or 1 and no worsening of hepatic fibrosis) at Week 52/ET. The reversal of NASH was defined as the absence of hepatocellular ballooning (score of 0) and no or minimal inflammation (lobular inflammation score of 0 or 1).
Time frame: Week 52
Percentage of Participants With Improvement by at Least 1 Stage in Fibrosis From Baseline at Week 12 and Week 52
Proportion of subjects with improvement by at least 1 stage in fibrosis without worsening of NASH (ie, improvement by at least 1 fibrosis stage without worsening of NAS) at Week 52/ET - Cochran-Mantel-Haenszel - mITTb Population There five liver fibrosis stages (F0: no scarring (no fibrosis); F1: minimal scarring; F2: scarring has occurred and extends outside the liver area (significant fibrosis); F3: fibrosis spreading and forming bridges with other fibrotic liver areas (severe fibrosis); F4: cirrhosis or advanced scarring)
Time frame: Week 52
| Milestone | Period 1: Seladelpar 10 mg | Period 1: Seladelpar 20 mg | Period 1: Seladelpar 50 mg | Period 1: Placebo | Period 2: Seladelpar 50 mg |
|---|---|---|---|---|---|
| Started | 53 | 51 | 50 | 27 | 0 |
| Completed | 27 | 34 | 32 | 17 | 0 |
| Not completed | 26 | 17 | 18 | 10 | 0 |
| Milestone | Period 1: Seladelpar 10 mg | Period 1: Seladelpar 20 mg | Period 1: Seladelpar 50 mg | Period 1: Placebo | Period 2: Seladelpar 50 mg |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 12 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 12 |
Evaluate the effect of seladelpar on hepatic fat fraction, as assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at Week 12 in the double-blind (DB) phase. MRI-PDFF Relative (Percent) Change From Baseline to Week 12 - ANCOVA - mITT Population MRI-PDFF exam was used to quantify the hepatic proton density fat fraction noninvasively. The fat fraction is the proportion of mobile protons in liver tissue attributable to fat and thus, is a noninvasive magnetic resonance-based biomarker of liver triglyceride concentration.
| percentage of change from Baseline | Seladelpar 10 mg | Seladelpar 20 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|---|
| Percentage Change From Baseline in Magnetic Resonance Imaging-proton Density Fat Fraction (MRI-PDFF) | -9.76 ± 4.153 | -14.24 ± 4.329 | -13.00 ± 4.305 | -20.78 ± 5.555 |
Histopathology nonalcoholic fatty liver disease activity score (NAS) change from baseline ≤-2 (Improvements of 2 points or more in NAS) - mITT Population Total NAS score represents the sum of scores for steatosis, lobular inflammation, and ballooning, and ranges from 0-8. Diagnosis of NASH (or, alternatively, fatty liver not diagnostic of NASH) should be made first, then NAS is used to grade activity. NAS scores of 0-2 occurred in cases largely considered not diagnostic of NASH, scores of 3-4 were evenly divided among those considered not diagnostic, borderline, or positive for NASH. Scores of 5-8 occurred in cases that were largely considered diagnostic of NASH
| Percentage of Participants | Seladelpar 10 mg | Seladelpar 20 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Improvement of 2 Points or More in the Nonalcoholic Fatty Liver Disease Activity Score (NAS) | 23.1 | 45.2 | 37.0 | 32.0 |
Alanine Aminotransferase (ALT) Relative (percent) change of from Baseline to Weeks 12 and Week 52 - mITT Population A decreased serum levels of alanine aminotransferase (ALT) is a marker of liver function improvement.
| percentage of change from Baseline | Seladelpar 10 mg | Seladelpar 20 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|---|
| Week 12 | -24.05 ± 4.154 | -32.92 ± 4.075 | -38.29 ± 3.907 | -9.57 ± 5.034 |
| Week 52 | -28.60 ± 5.044 | -43.93 ± 4.844 | -40.60 ± 4.682 | -2.26 ± 6.252 |
Relative (Percent) Change of Aspartate Aminotransferase (AST) From Baseline to Weeks 12 and Week 52 - mITT Population A decreased serum levels of Aspartate Aminotransferase (AST) is a marker of liver function improvement.
| percentage of change from baseline | Seladelpar 10 mg | Seladelpar 20 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|---|
| Week 12 | -14.02 ± 4.793 | -16.03 ± 4.686 | -17.88 ± 4.491 | -14.75 ± 5.834 |
| Week 52 | -20.62 ± 5.988 | -26.43 ± 5.698 | -18.43 ± 5.536 | -4.54 ± 7.490 |
Relative (Percent) Change of Gamma Glutamyl Transferase (GGT) From Baseline to Weeks 12 and Week 52 - mITT Population A decreased serum levels of Gamma Glutamyl Transferase (GGT) is a marker of liver function improvement.
| Percentage of change from Baseline | Seladelpar 10 mg | Seladelpar 20 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|---|
| Week 12 | -28.67 ± 3.848 | -37.78 ± 3.760 | -42.50 ± 3.626 | -6.40 ± 4.630 |
| Week 52 | -27.93 ± 5.674 | -45.84 ± 5.401 | -35.11 ± 5.255 | 0.71 ± 7.093 |
Number of Participants with a relative decrease in MRI-PDFF ≥30% (ie, percent change ≥ 30%) at Weeks 12, and 52/ET (Early Termination) in the DB phase - mITT Population. MRI-PDFF exam was used to quantify the hepatic proton density fat fraction noninvasively. The fat fraction is the proportion of mobile protons in liver tissue attributable to fat and thus, is a noninvasive magnetic resonance-based biomarker of liver triglyceride concentration. MRI-PDFF response defined as ≥30% relative decline in MRI-PDFF is associated with ≥1 stage improvement in fibrosis and may be used as a surrogate marker of fibrosis regression in early phase clinical trials for NASH
| Participants | Seladelpar 10 mg | Seladelpar 20 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|---|
| Week 12 | 12 | 12 | 9 | 8 |
| Week 52/ET | 8 | 19 | 8 | 5 |
Percentage Change from Baseline in MRI-PDFF to Weeks 52//ET - mITT Population MRI-PDFF exam was used to quantify the hepatic proton density fat fraction noninvasively. The fat fraction is the proportion of mobile protons in liver tissue attributable to fat and thus, is a noninvasive magnetic resonance-based biomarker of liver triglyceride concentration.
| percentage of change from Baseline | Seladelpar 10 mg | Seladelpar 20 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|---|
| Percentage Change From Baseline in Magnetic Resonance Imaging-proton Density Fat Fraction (MRI-PDFF) at Week 52 | -9.76 ± 27.323 | -23.98 ± 30.666 | -7.99 ± 30.650 | -18.30 ± 27.872 |
Liver Biopsy Responders with reversal of NASH (ballooning score of 0 and lobular inflammation score of 0 or 1 and no worsening of hepatic fibrosis) at Week 52/ET. The reversal of NASH was defined as the absence of hepatocellular ballooning (score of 0) and no or minimal inflammation (lobular inflammation score of 0 or 1).
| Participants | Seladelpar 10 mg | Seladelpar 20 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|---|
| Number of Liver Biopsy Responders With Reversal of NASH Reversal of NASH (Ballooning Score of 0 and Lobular Inflammation Score of 0 or 1) and no Worsening of Hepatic Fibrosis at Week 52 | 4 | 8 | 12 | 2 |
Proportion of subjects with improvement by at least 1 stage in fibrosis without worsening of NASH (ie, improvement by at least 1 fibrosis stage without worsening of NAS) at Week 52/ET - Cochran-Mantel-Haenszel - mITTb Population There five liver fibrosis stages (F0: no scarring (no fibrosis); F1: minimal scarring; F2: scarring has occurred and extends outside the liver area (significant fibrosis); F3: fibrosis spreading and forming bridges with other fibrotic liver areas (severe fibrosis); F4: cirrhosis or advanced scarring)
| Participants | Seladelpar 10 mg | Seladelpar 20 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Improvement by at Least 1 Stage in Fibrosis From Baseline at Week 12 and Week 52 | 9 | 10 | 17 | 5 |
Collected over Through DB Phase (from first dose of DB phase study drug, and up to 30 days after last dose of DB phase study drug or 1 day before the first dose of OLE phase, whichever was earlier), up to 56 weeks. AEs are only summarized in DB phase, not OLE phase.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Seladelpar 10 mg | 0/53 (0%) | 1/53 (1.9%) | 45/53 (84.9%) |
| Seladelpar 20 mg | 0/51 (0%) | 3/51 (5.9%) | 49/51 (96.1%) |
| Seladelpar 50 mg | 0/50 (0%) | 5/50 (10%) | 48/50 (96%) |
| Placebo | 0/27 (0%) | 0/27 (0%) | 25/27 (92.6%) |
| Event | Seladelpar 10 mg | Seladelpar 20 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|---|
| DiverticulitisInfections and infestations | 0/53 | 0/51 | 2/50 | 0/27 |
| Faeces discolouredGastrointestinal disorders | 0/53 | 0/51 | 1/50 | 0/27 |
| Non-cardiac chest painGeneral disorders | 0/53 | 1/51 | 1/50 | 0/27 |
| Gastroenteritis Escherichia coliInfections and infestations | 0/53 | 0/51 | 1/50 | 0/27 |
| Intentional overdoseInjury, poisoning and procedural complications | 0/53 | 0/51 | 1/50 | 0/27 |
| Procedural painInjury, poisoning and procedural complications | 0/53 | 0/51 | 1/50 | 0/27 |
| Obstructive pancreatitisGastrointestinal disorders | 0/53 | 1/51 | 0/50 | 0/27 |
| DizzinessNervous system disorders | 0/53 | 1/51 | 0/50 | 0/27 |
| PneumoniaInfections and infestations | 1/53 | 0/51 | 0/50 | 0/27 |
| Post procedural complicationInjury, poisoning and procedural complications | 1/53 | 0/51 | 0/50 | 0/27 |
| Event | Seladelpar 10 mg | Seladelpar 20 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|---|
| HeadacheNervous system disorders | 6/53 | 10/51 | 2/50 | 2/27 |
| NauseaGastrointestinal disorders | 7/53 | 8/51 | 6/50 | 4/27 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 8/53 | 2/51 | 6/50 | 4/27 |
| Back painMusculoskeletal and connective tissue disorders | 1/53 | 5/51 | 2/50 | 4/27 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/53 | 7/51 | 4/50 | 1/27 |
| Urinary tract infectionInfections and infestations | 0/53 | 5/51 | 6/50 | 3/27 |
| DiarrhoeaGastrointestinal disorders | 2/53 | 6/51 | 2/50 | 0/27 |
| Abdominal pain upperGastrointestinal disorders | 6/53 | 4/51 | 3/50 | 3/27 |
| HypertensionVascular disorders | 6/53 | 2/51 | 1/50 | 3/27 |
| ConstipationGastrointestinal disorders | 3/53 | 4/51 | 5/50 | 3/27 |
| Age, Continuous(years) | Seladelpar 10 mg | Seladelpar 20 mg | Seladelpar 50 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 53.3 ± 12.48 | 56.6 ± 11.74 | 53.7 ± 11.18 | 53.9 ± 10.27 | 54.4 ± 11.60 |
| Sex: Female, Male(Participants) | Seladelpar 10 mg | Seladelpar 20 mg | Seladelpar 50 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 36 | 35 | 33 | 18 | 122 |
| Male | 17 | 16 | 17 | 9 | 59 |
| Race/Ethnicity, Customized(Participants) | Seladelpar 10 mg | Seladelpar 20 mg | Seladelpar 50 mg | Placebo | Total |
|---|---|---|---|---|---|
| White | 50 | 47 | 49 | 27 | 173 |
| Black or African American | 1 | 1 | 0 | 0 | 2 |
| Asian | 1 | 1 | 1 | 0 | 3 |
| American Indian or Alaska native | 1 | 1 | 0 | 0 | 2 |
| Multiple | 0 | 1 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Seladelpar 10 mg | Seladelpar 20 mg | Seladelpar 50 mg | Placebo | Total |
|---|---|---|---|---|---|
| United States | 53 | 51 | 50 | 27 | 181 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2018 to primary completion in May 2019, 12 months.
Results were first posted in Jul 2022, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Seladelpar
Non-alcoholic Fatty Liver Disease →